RSV Vaccination in Systemic Autoimmune Rheumatic Diseases: A Systematic Review

Clicks: 15
ID: 329037
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #246 of 339 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 339 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Respiratory syncytial virus (RSV) vaccination is available for older adults. Patients with systemic autoimmune rheumatic diseases (SARDs), including those receiving immunosuppressive therapies, were excluded from trials. Evidence to guide vaccination decisions is limited. We conducted a systematic review evaluating RSV epidemiology, vaccine effectiveness, immunogenicity, and safety in adults with SARDs. Databases were searched from inception to 28th January 2026. Observational studies, clinical trials, and pharmacovigilance reports were included. Evidence specific to disease-modifying antirheumatic drugs (DMARDs) was examined where available. Of the 249 unique records returned, 43 met the inclusion criteria. Six studies were identified in the supplementary search, yielding 49 studies in total. Only one study reported RSV outcomes in SARD patients. No study evaluated vaccine effectiveness stratified by DMARD-class. Observational data suggest autoimmune and immunocompromising conditions are associated with increased RSV-associated hospitalisation, although attribution is uncertain due to bias and data limitations. RSV vaccines demonstrated first-season effectiveness of 60–73% in immunocompromised adults, with evidence of attenuated and more rapidly waning protection compared with immunocompetent populations. Immunogenicity studies from RSV and other vaccine platforms indicate reduced seroconversion in immunosuppressed patients. No consistent autoimmune safety signals were identified, though data in SARD populations remain limited. RSV poses a relevant, though incompletely quantified, risk for SARD patients. Vaccination appears effective and safe in immunocompromised populations, but protection may wane more rapidly. The absence of DMARD-specific data represents an evidence gap. Until further evidence emerges, vaccination should be considered for eligible patients using a personalised framework.
Reference Key
openalex_W7213531793 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Victoria Allen, Maryam Adas, Liyang Pan, Nilay Joshi, M. Russell, Katie Bechman, James Galloway
Are you one of these authors? Claim your profile
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag513
URL
https://doi.org/10.1093/rheumatology/keag513
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.